Strategic BARDA funding Explore partnerships and co-development opportunities around SCY-247 leveraging BARDA support and the US preparedness angle. Highlight potential for government-funded expansion, supply agreements, and priority access programs in high-risk fungal infection settings.

Oral IV versatility Position SCY-247 as a versatile antifungal with both oral and IV formulations to target invasive candidiasis across hospital and outpatient settings. Propose licensing or collaborative development deals to broaden indications and accelerate market entry.

Rare disease focus Target rare disease care networks and patient access programs by offering differentiated, clinically meaningful therapies. Identify potential partnerships with specialty centers, payer strategies, and compassionate use pathways to optimize adoption.

Leadership expansion Leverage recent leadership appointments in finance and R&D to open touchpoints for strategic collaborations, capital markets outreach, and joint ventures. Propose executive briefings to align on funding milestones and development timelines.

Orphan drug momentum Capitalize on Orphan Drug designation for SCY-770 by pursuing co-development or milestone-based deals with biotech and pharma partners focused on nephrology and genetic rare diseases, leveraging potential tax credits and expedited pathways to market.